Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Apr;67(4):469-72.
doi: 10.1111/j.1365-2125.2009.03367.x.

Lack of age and gender effects on single-dose pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem

Affiliations
Randomized Controlled Trial

Lack of age and gender effects on single-dose pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem

Navita L Mallalieu et al. Br J Clin Pharmacol. 2009 Apr.

Abstract

Aims: To investigate the effect of age and gender on the tolerability, safety and pharmacokinetics (PK) of tomopenem (RO4908463/CS-023), a novel carbapenem antibiotic, and its major metabolite.

Methods: Forty-two subjects were assigned to one of the following three groups: young men, elderly men and elderly women. The PK, safety and tolerability of an intravenous infusion of 1500 mg tomopenem and its resultant major metabolite (open beta-lactam ring) were assessed.

Results: Minor differences in exposure of both tomopenem and the major metabolite were seen. The area under the curve (AUC) of tomopenem was 22% higher in elderly men compared with young men, and 19% higher in elderly women relative to the elderly men. Total clearance of tomopenem decreased with decreasing creatinine clearance. In the two male groups, renal clearance values of tomopenem were similar (3.52 and 3.67 l h(-1)) and higher than in the elderly female group (2.83 l h(-1)). The mean half-lives ranged from 2.03 (healthy young men) to 2.41 h (elderly men). The difference in AUC of tomopenem can be explained by differences in the mean creatinine clearances of 116 (young men), 101 (elderly men) and 84.7 (elderly women) ml min(-1) 1.73 m(-2), respectively.

Conclusions: While some PK parameters were statistically different among the three groups, the differences were mostly minor and unlikely to be clinically meaningful. The difference in the PK can be largely attributed to the difference in creatinine clearance of these groups.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relation between creatinine clearance and total clearance and AUC and creatinine clearance of tomopenem following a single intravenous dose of 1500 mg of tomopenem (n= 12)

Similar articles

Cited by

References

    1. Ohya S, Fukuoka T, Kawada H, Kubota M, Kitayama A, Abe T, Kuwahara S. 40th Intersci Conf Antimicrob Agents Chemother, abstr F-1232 R-115685, a novel parenteral carbapenem: in vivo antibacterial activity. Abstr 40th Intersci Conf Antimicrob Agents Chemother, abstr F-1232. 2000;40:205.
    1. Noel AR, Bowker KE, MacGowan AP. The RO4908463 (CS-023) T > MIC antibacterial effect relationship for MRSA established in an in vitro pharmacokinetic model of infection. Abstr 46th Intersci Conf Antimicrob Agents Chemother abstr A-638. 2006;46
    1. Thomson KS, Moland ES. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. J Antimicrob Chemother. 2004;54:557–62. - PubMed
    1. Mouton JW, Touw DJ, Horrevorts AM, Vinks AATMM. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet. 2000;39:185–201. - PubMed
    1. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology. 1999;45:243–53. - PubMed

Publication types